Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 158INDUSTRY 109NETWORK 8NIH 5UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 12Rituximab 9fludarabine 6Prednisone 5Vinorelbine 4Vincristine 4Epirubicin 4zanubrutinib 3Nivolumab 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3Drug Therapy 3pegylated granulocyte colony-stimulating factor 2fludarabine phosphate 2Thiotepa 2Metformin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Doxorubicin 2Cytarabine 2Bortezomib 2treosulfan 1plerixafor 1pegfilgrastim 1parsaclisib 1obinutuzumab 1nilotinib 1liposomal doxorubicin 1ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Bendamustine Hydrochloride × Lymphoid × Clear all
NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Sheba Medical Center

Phase 2 Unknown
72 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡